Performance-driven technology that aims to provide faster, easier, and safer vascular interventions.

Our goal is to revolutionize the way we navigate complex and calcific arteries, empowering interventionalists to deliver more effective treatments to patients.

– Dr. Tim Fischell, Chief Medical Officer

Vantis Vascular is revolutionizing the treatment of complex and calcific arteries with next-generation technology that allows physicians to experience superior delivery, safety, and efficiency.

    Coronary Interventions

    PCIs are becoming increasingly more challenging, requiring specialized tools to deliver lifesaving therapies.


    percutaneous coronary interventions (PCI) yearly in the U.S.1


    of cases experience inability to advance guide extension catheters distally1

    Peripheral Below-the-Knee (BTK)

    Peripheral BTK procedures are becoming more calcific and challenging, requiring specialized tools to deliver treatment.


    Americans 60+ with Peripheral Artery Disease (PAD)3


    BTK cases yearly in the U.S.1


    BTK vessels with moderate-to-severe calcification4


    Intravascular Lithotripsy (IVL)

    IVL is a modification therapy used to break up calcium deposits throughout the body. Despite its success, reaching distal anatomy has been a challenge.


    IVL compound annual growth rate over the next decade5,6


    of cases remain uncrossable with current IVL technologies due to heavy calcification7

    A true system approach, providing effortless delivery of therapeutic devices to distal coronary or peripheral anatomies

    Watch Product Animation
    Product Image of Seamless Profile
    Product Image of Inner Microcatheter
    Product Image of Outer Delivery Catheter

    Products are currently in development and are not commercially available in any geography.

    We are Vantis

    Founded by physicians to develop performance-driven technology for vascular interventions.

    We design solutions to provide faster, easier, and safer procedures, specifically targeting navigation challenges in complex, calcified, and tortuous anatomies.

    Our Values
    • Performance Engineering

      Developing cutting-edge tools to help physicians treat patients faster, easier, and safer than ever before.

    • Removing Barriers

      Creating practice-changing products that have an immediate impact on interventional procedures.

    • Blazing New Trails

      Leveraging a diverse, world-class team to create new solutions to existing problems in interventional medicine.

    Jason Turner

    Chief Executive Officer

    Jason comes to Vantis Vascular with over 20 years of experience in driving medical innovation and navigating dynamic industry trends. Jason also serves as a Board Member for Efemoral Medical, a developer of advanced interventional bioresorbable therapies. Prior to his role at Vantis, Jason was Chief Operating Officer at Venclose (acquired by BD), where he was responsible for business planning and execution. He brings a unique breadth and depth of experience building and leading lean, scalable teams and has spent the last 15 years with medical technology start-ups in the vascular space. Jason has held various operational and commercial leadership roles, including playing an instrumental role in the growth and success of Access Closure (acquired by Cardinal Health). Jason holds a Bachelor of Science in Finance degree from San Jose State University.

    Dr. Tim Fischell

    Chief Medical Officer

    Dr. Fischell, M.D., FACC, MSCAI, FNAI, is a distinguished physician and Professor of Medicine, is currently serving as Chief Medical Officer of Vantis Vascular. With a remarkable career spanning decades, Dr. Fischell has left an indelible mark on the medical field. Dr. Fischell’s academic journey boasts credentials from renowned institutions like Cornell University Medical College, Massachusetts General Hospital, Stanford University Hospital, and Vanderbilt University. He enjoys teaching and serves as the Program Director of the Interventional Cardiology Fellowship training program at Michigan State University, Borgess Heart Institute. He serves as a driving force behind medical innovation, as his contributions extend beyond academia. He has founded or co-founded numerous medical device companies, and holds over 100 patents, revolutionizing the landscape of cardiovascular intervention. As a clinician, researcher, entrepreneur, and prolific inventor, Dr. Fischell continues to reshape cardiovascular interventions and improve patient care.

    Dr. Frank Saltiel

    Chief Clinical Officer

    Dr. Saltiel is a distinguished cardiologist and visionary leader, currently serving as the Chief Clinical Officer at Vantis Vascular. He has comprehensive experience as an interventional cardiologist with special expertise in complex coronary interventions and structural heart disease. Based in Kalamazoo, Michigan, Dr. Saltiel serves as the Medical Director of Cardiology as well as the Chairman of the Ascension Borgess Heart Institute at Ascension Borgess Hospital. With a focus on clinical research, medical education, and medical device advancement, Dr. Saltiel serves as an Associate Clinical Professor of Medicine at both The Michigan State University College of Human Medicine and The Homer Stryker Western Michigan University School of Medicine. He is also a co-founder and general partner with the Novus Biotechnology Fund. Throughout his career, he has maintained extensive involvement in device innovation keeping him at the forefront of modern cardiology.

    Gary McCord

    Chief Commercial Officer

    Gary leverages nearly 30 years of experience in sales, marketing, and management within the medical device industry. Prior to his role at Vantis Vascular, he led Venclose (acquired by BD) in the same role. He was part of the executive team at TriReme Medical, a California-based subsidiary of QT Vascular, which develops and manufactures therapies for complex vascular disease. Gary was VP of Business Development at Sapheon (acquired by Covidien/Medtronic), a developer of closure systems for treatment of venous reflux disease. His expertise extends to Cardiovascular Systems, Fox Hollow Technologies, Pilot Cardiovascular Systems, and other innovative cardiology enterprises which were later acquired by industry giants such as C.R. Bard, Boston Scientific, Guidant, and St. Jude Medical. Gary earned his Bachelor of Arts in Communications from the University of Missouri, Columbia.

    Mike Mirizzi

    Chief Technology Officer

    Mike has over 30 years of hands-on experience and technical management in medical device R&D and product development in start-up, medium and large companies spanning multiple clinical indications. Before joining Vantis Vascular, Mike served as Vice President of R&D for Venclose (acquired by BD), where he was responsible for building and developing an R&D team commercializing an ablation technology for treating patients with chronic venous insufficiency. Over his career, Mike has held multiple positions of increasing responsibility including at Spirox (acquired by Stryker), Qool Therapeutics, VNUS Medical (acquired by Covidien), Guidant Corporation, Target Therapeutics and Alcon Surgical. Mike has a Bachelor of Science in Industrial Engineering from California Polytechnic State University, San Luis Obispo and is an inventor on over 70 issued and pending US and Foreign patents.

    James Abrams

    Vice President of Operations

    James brings over 15 years of experience in manufacturing engineering and operations management with specific expertise in medical device design transfer and product lifecycle management. Prior to Vantis Vascular, he held positions with increasing responsibility at start-up and industry-leading companies including Venclose (acquired by BD), VNUS Medical (acquired by Covidien, now part of Medtronic), Miramar Labs (acquired by Sientra), Abbott, and Covidien (acquired by Medtronic). He brings a data driven, lean manufacturing approach to develop business opportunities and long-term business relationships. James holds a Master of Science degree in Mechanical Engineering from San Jose State University.

    Angela Thompson

    Vice President of Quality

    Angela brings extensive leadership in quality engineering, project management, manufacturing engineering, and regulatory compliance within the medical device industry. With a commitment to excellence, she drives quality initiatives to ensure the highest standards in product development. Angela’s journey includes 20+ years’ experience in pivotal roles at numerous startup and fortune 500 medical device companies such as Ablation Frontiers (acquired by Medtronic), Accriva Diagnostics (acquired by Werfen), and Illumina. Her expertise extended to being CEO & Founder at Cateva Solutions LLC, a consulting firm driven to launch innovative healthcare geared towards a diverse and inclusive population. Angela’s passion for fostering diversity and inclusion is evident through her tenure as the Region VI Chairperson of the National Society of Black Engineers which encompasses 13 western states and served on the National Board. She is also involved in the San Diego Biotechnology and Engineering Network, the Forbes Women’s Forum, and the Regulatory Affairs Professional Society. Angela holds a Bachelor of Science in Bioengineering and Biology from San Diego State University with extended learning Certifications in Lean Six Sigma, Advance Cardiac Physiology, and Comprehensive Monitoring for Medical Devices.

    Katie Arnold

    Marketing Consultant

    Katie Arnold is the Founder and CEO of SPRIG Consulting and a proven executive with over 25 years of strategic marketing and commercial launch experience in the medical products space. Prior to founding SPRIG, Katie’s career included sales and marketing management roles with cardiovascular medical device companies Guidant Corporation (acquired by Abbott Laboratories and Boston Scientific) and Kensey Nash Corporation (acquired by Spectranetics Corporation/Royal Philips). Katie is currently an adjunct Faculty member at Northwestern University’s Kellogg School of Business, teaching medical product commercialization and financing. She is also an organizing member of the Medtech Women non-profit organization. Katie received her MBA from the Kellogg Business School, Northwestern University, and holds a Bachelor’s degree in Environmental Sciences and Chemistry from the University of Vermont.

    Amir Kaki, MD, FSCAI

    Heart & Vascular Institute
    Detroit, MI

    Gautam Kumar, MBBS, FSCAI

    Emory University Hospital
    Atlanta, GA

    Kenny Rosenfield, 

    Massachusetts General Hospital
    Boston, MA

    Paul Terstein, MD

    Scripps Health
    San Diego, CA

    Ron Waksman, MD, MSCAI

    MedStar Heart Institute
    Washington, DC